RecruitingNCT07221877
KarXT and urinary safety in people with schizophrenia
About this title
Read the official source — NCT07221877Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
What will I do during this study?
You receive the study medication KarXT, which combines xanomeline and trospium chloride.
- Listed locations
- Little Rock and 15 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 20, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07221877
- Official title
Show the full official title
A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
Recruitment & locations
RecruitingLittle Rock · Bellflower · Garden Grove
12 more locations
- Orange
- Redlands
- Torrance
- West Covina
- Boynton Beach
- Lauderhill
- Chicago
- Las Vegas
- Marlton
- Philadelphia
- Austin
- DeSoto
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline/trospium chloride.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
